Table 1.

Review of the pharmacokinetics of lapatinib at the dose of 1250 mg/day, approved by the Food and Drug Administration

Absorption	Oral, not available in IV form
Tmax	3–4 hours
Steady-state Cmax	2.43 μg/mL
AUC	36.2 μg h/mL
Distribution	Highly bound (>99%) to albumin
Volume of distribution	> 2200 L
Metabolism
Primary	CYP3A4 (70% of metabolism)
Secondary	CYP3A5, CYP2C19, CYP2C8
Elimination	Primarily hepatic
Single dose t1/2	14.2 hours
Multiple doses t1/2	24 hours

Abbreviations: t_1/2, elimination half-life; AUC, area under the concentration-time curve; IV, intravenous; T_max, time to peak concentration; C_max, maximum concentration.